Icon

FEMARA (nda020726)- (2.5MG)

LETROZOLE NOVARTIS PHARMS
2.5MG
Yes No
2011-Jun-03 Expired
None None
None No
Femara is an aromatase inhibitor indicated for:  Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer  Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy  First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer
7 1 6
Total Other Developers 10
Drugs with Suitability No
2.5MG ** ** - 5 -
NDA Sales Available Total Generic Sales Available
Yes 5
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** **** ****** ****** ****** ******* ******* *********** **** **. **-*-*, ***** ** ***** ********** ******, *****, ********, *** ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** **** **** **.*****'* ************ ******* *********** ** ** ** & ** ** **, ***** - ***, ****, *******,, *************, ****** ******* *** ***, ***** (***) ***
****** ***** ****** *** ***** ****** ******* *********** ****** ********, ******, **********, ********* *** ***, ***** (***) ***
****** ***** ****** *** ***** ****** ******* *********** **** **.: ** & **, ****, ***** ****** ****, ********, *************, ****** ******* ******, ***** (***) ***
****** ******* ****** ******* ****** ***-*********** ********** **.,***. *********** **.** **** ****, ******** ****, *****, *******, ******, ***** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-*, **. **. ***, *** & ***, ******* *******, ********* ******, *******-**********, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.